Calidi Biotherapeutics Statistics
Total Valuation
CLDI has a market cap or net worth of $2.85 million. The enterprise value is -$1.53 million.
Important Dates
The last earnings date was Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CLDI has 15.38 million shares outstanding. The number of shares has increased by 445.70% in one year.
| Current Share Class | 15.23M |
| Shares Outstanding | 15.38M |
| Shares Change (YoY) | +445.70% |
| Shares Change (QoQ) | +44.73% |
| Owned by Insiders (%) | 2.01% |
| Owned by Institutions (%) | 7.67% |
| Float | 14.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.44 |
| P/TBV Ratio | 0.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.92, with a Debt / Equity ratio of 0.46.
| Current Ratio | 1.92 |
| Quick Ratio | 1.73 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -70.93 |
Financial Efficiency
Return on equity (ROE) is -312.39% and return on invested capital (ROIC) is -126.10%.
| Return on Equity (ROE) | -312.39% |
| Return on Assets (ROA) | -98.18% |
| Return on Invested Capital (ROIC) | -126.10% |
| Return on Capital Employed (ROCE) | -336.49% |
| Weighted Average Cost of Capital (WACC) | 10.83% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$841,103 |
| Employee Count | 29 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CLDI has paid $16,000 in taxes.
| Income Tax | 16,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -96.13% in the last 52 weeks. The beta is 1.38, so CLDI's price volatility has been higher than the market average.
| Beta (5Y) | 1.38 |
| 52-Week Price Change | -96.13% |
| 50-Day Moving Average | 0.23 |
| 200-Day Moving Average | 1.10 |
| Relative Strength Index (RSI) | 40.04 |
| Average Volume (20 Days) | 2,247,382 |
Short Selling Information
The latest short interest is 3.04 million, so 19.76% of the outstanding shares have been sold short.
| Short Interest | 3.04M |
| Short Previous Month | 244,357 |
| Short % of Shares Out | 19.76% |
| Short % of Float | 21.65% |
| Short Ratio (days to cover) | 0.34 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -19.37M |
| Pretax Income | -19.09M |
| Net Income | -24.39M |
| EBITDA | -17.68M |
| EBIT | -19.37M |
| Earnings Per Share (EPS) | -$3.96 |
Full Income StatementBalance Sheet
The company has $6.63 million in cash and $2.26 million in debt, with a net cash position of $4.37 million or $0.28 per share.
| Cash & Cash Equivalents | 6.63M |
| Total Debt | 2.26M |
| Net Cash | 4.37M |
| Net Cash Per Share | $0.28 |
| Equity (Book Value) | 4.94M |
| Book Value Per Share | 0.42 |
| Working Capital | 3.52M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$18.28 million and capital expenditures -$118,000, giving a free cash flow of -$18.40 million.
| Operating Cash Flow | -18.28M |
| Capital Expenditures | -118,000 |
| Depreciation & Amortization | 1.68M |
| Net Borrowing | -867,000 |
| Free Cash Flow | -18.40M |
| FCF Per Share | -$1.20 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
